2014

Aktas O. Natalizumab in clinical practice: managing the risks, enjoying the benefits. Journal of Neurology, Neurosurgery & Psychiatry 2014; 85: 1181.

Albrecht P, Balk L, Oberwahrenbrock T, Petzold A, Paul F. Retinal segmentation to demonstrate hyperplasia in ataxia of Charlevoix-Saguenay: critique on study methodology and results. Investigative Ophthalmology & Visual Science 2014; 55: 4728.

Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurology 2014; 14: 1058.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurology 2014; 71: 306-314.

Balk LJ, Petzold A, Oberwahrenbrock T, Brandt AU, Albrecht P. Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. American Journal of Ophthalmology 2014; 158: 845.

Berndt C, Lillig CH, Flohé L. Redox regulation by glutathione needs enzymes. Frontiers in Pharmacolgy 2014; 5: 168.

Braun SA, Baran AM, Boettcher C, Kieseier BC, Reifenberger J. Multilokuläre Erythemata migrantia und Fazialisparese. Hautarzt 2014; 65: 268-271.

Butz M, Timmermann L, Gross J, Pollok B, Südmeyer M, Kircheis G, Häussinger D, Schnitzler A. Cortical activation associated with asterixis in manifest hepatic encephalopathy. Acta Neurologica Scandinavica 2014; 130: 260-267.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Nurosurgery & Psychiatry 2014, in press.

Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A: for the ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology 2014; 13: 657-665.

Caspers S, Moebus S, Lux S, Pundt N, Schütz H, Mühleisen TW, Gras V, Eickhoff SB, Romanzetti S, Stöcker T, Stirnberg R, Kirlangic ME, Minnerop M, Pieperhoff P, Mödder U, Das S, Evans AC, Jöckel KH, Erbel R, Cichon S, Nöthen MM, Sturma D, Bauer A, Jon Shah N, Zilles K, Amunts K. Studying variability in human brain aging in a population-based German cohort-rationale and design of 1000 BRAINS. Frontiers in Aging Neuroscience2014; 6: 149.

Chen G, Arima H, Wu G, Heeley E, Delcourt C, Zhang P, Rabinstein AA, Robinson T, Stapf C, [Jander S]; for the INTERACT2 Investigators. Subarachnoid extension of intracerebral hemorrhage and 90-day outcomes in INERACT2. Stroke 2014; 45: 258-260.

Clanet MC, Wolinsky JS, Ashton RJ, Hartung HP, Reingold SC. Risk evaluation and monitoring in multiple sclerosis therapeutics. Multiple Sclerosis 2014; 20: 1306-1311.

Collongues N, Marignier R, Jacob A, Leite MI, Sivas A, Paul F, Zephir H, Akman-Demirs G, Elsone L, Jarius S, Papeix C, Mutch K, Saips S, Wildemann B, Kitley J, Karabudak R, Aktas O, Kuscu D, Altintas A, Palace J, Confavreux C, De Seze J. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Multiple Sclerosis 2014; 20: 1086-1094.

Curtin F, Hartung HP. Novel therapeutic options for multiple sclerosis. Expert Review of Clinical Pharmacology 2014; 7: 91-104.

Cwik JC, Sartory G, Schürholt B, Knuppertz H, Seitz RJ. Posterior midline activation during symptom provocation in acute stress disorder: an fMRI study. Frontiers in Psychiatry 2014; 5: 49.

Dehmel T, Döbert M, Pankratz S, Leussink VI, Hartung HP, Wiendl H, Kieseier BC. Monomethylfumarate reduces in vitro migration of mononuclear cells. Neurological Sciences 2014; 35: 1121-1125.

Derksen A, Ritter C, Athar P, Kieseier BC, Mancias P, Hartung HP, Sheikh KA, Lehmann HC. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle & Nerve2014; 50: 780-784.

De Stefano N, Airas L, Grigoriadis N, Mattle HP, O'Riordan J, Oreja-Guevara C, Sellebjerg F, Stankoff B, Walczak A, Wiendl H, Kieseier BC. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014; 28: 147-156.

Doerner M, Beckmann K, Knappertz V, Kappos L, Hartung HP, Filippi M, O'Connor PW, Arnason B, Cook S, Jeffery D, Comi G, Limmroth V. Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND Study. European Neurology 2014; 71: 173-179.

Dörr J, Ringelstein M, DuningT, Kleffner I. Update on Susac syndrome: new insights in brain and retinal imaging and treatment options. Journal of Alzheimer's Disease 2014; 42: 99-108.

Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; for the BENEFIT Study Group. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Journal of Neurology, Neurosurgery and Psychiatry 2014; 85: 1183-1189.

Eisele P, Szabo K, Hornberger E, Griebe M, Kieseier BC, Hennerici MG, Gass A. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy. Journal of Neuroimaging 2014; 24: 425-428.

Estrada V, Müller HW. Spinal cord injury - there is not just one way of treating it. F1000Prime Reports 2014; 6: 84.

Estrada V, Brazda N, Schmitz C, Heller S, Blazyca H, Martini R, Müller HW. Long-lasting significant functional improvement in chronic severe spinal cord injury following scar resection and polyethylene glycol implantation. Neurobiology of Disease 2014; 67: 165-179.

Fox RJ, Cree B, de Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology2014; 82: 1491-1498.

Gibbs E, Karim ME, Oger J; the Steering Committee of the BENEFIT study. Antiibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained Nabs. Clinical Immunology 157; 91-101.

Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J, Alvarez-Cermeno JC, Villar L, Galimberti D, Myhr KM, Dujmovic I, Fazekas F, Ionete C, Menge T, Kuhle J, Keir G, Deisenhammer F, Teunissen C, Giovannoni G. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 2014; 83: 1210-1216.

Gobrecht P, Leibinger M, Andreadaki A, Fischer D. Maintenance of GSK3 activity markedly facilitates peripheral nerve regeneration. Nature Communications 2014; 5: 4561.

Goodin DS, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, Knappertz V, Cutter G, Pleimes D. Causes of death among commercially insured multiple sclerosis patients in the Unites States. PLoS ONE 2014; 9: e105207.

Goubergrits L, Schaller J, Kertzscher U, Woelken T, Ringelstein M, Spuler A. Hemodynamic impact of cerebral aneurysm endovascular treatment devices: coils and flow diverters. Expert Review of Medical Devices 2014; 11: 361-373.

Grimaldi G, Argyropoulos GP, Boehringer A, Celnik P, Edwards MJ, Ferrucci R, Galea JM, Groiss SJ, Hiraoka K, Kassevetis P, Lesage E, Manto M, Miall RC, Priori A, Sadnicka A, Ugawa Y, Ziemann U. Non-invasive cerebellar stimulation - a consensus paper. Cerebellum2014; 13: 121-138.

Hacke W, Schellinger PD, Albers GW, Bornstein NM, Dahlof BS, Fulton R, Kasner SE, Shuaib A, Richieri SP, Dilly SG, Zivin J, Lees KR, Jander S; for the NEST3 Committees and Investigators. Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial. Stroke 2014; 45: 3187-3193.

Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung HP, Jarius S, Aktas O. Interferon-b-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurology 2014; 14: 247.

Hartung HP, Aktas O, Menge T, Kieseier BC. Immune regulation of multiple sclerosis. In: Goodin (ed.) Handbook of Clinical Neurology, Multiple Sclerosis and related disorders.Elsevier, Chicago 2014; 122: 3-14.

Hartung HP, Kieseier BC. The new therapeutic landscape in MS - exciting times and new perspectives. (Editorial) Current Opinion Neurology 2014; 27: 243-245.

Hartung HP. Interferon beta-1a for multiple sclerosis: old drug, new clothes. Lancet Neurology 2014; 13: 638-639

Hartung HP, Kieseier BC, Lehmann HC. Neuromuskuläre Erkrankungen bei Intensivpatienten. In: Marx, Muhl, Zacharowski, Zeuzem (eds.) Die Intensivmedizin. Springer Medizin Verlag, Heidelberg, 2014; 623-634.

Heers M, Hirschmann J, Jacobs J, Dümpelmann M, Butz M, von Lehe M, Elger CE, Schnitzler A, Wellmer J. Frequency domain beamforming of magnetoencephalographic beta band activity in epilepsy patients with focal cortical dysplasia. Epilepsy Research 2014; 108: 1195-1203.

Hefter H, Spiess C, Rosenthal D. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. Journal of Neural Transmission 2014; 121: 513-519.

Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121: 1414-1420.

Heim S, Pieperhoff P, Grande M, Kuijsten W, Wellner B, Sáez LE, Schulte S, Südmeyer M, Caspers S, Minnerop M, Binkofski F, Huber W, Amunts K. Longitudinal changes in brains of patients with fluent primary progressive aphasia. Brain and Language 2014; 131: 11-19.

Illes S, Jakob M, Beyer F, Gelfert R, Couillard-Despres S, Schnitzler A, Ritter M, Aigner L. Intrinsically active and pacemaker neurons in pluripotent stem cell-derived neuronal populations. Stem Cell Reports 2014; 2: 323-336.

Jander S, Stegemann E. Zerebrale arterielle Verschlusskrankheit bei koronarer Herzerkrankung. Deutsche Medizinische Wochenschrift 2014; 139: 1224-1227.

Jarius S, Kleffner I, Dörr JM, Sastre-Garriga J, Illes Z, Eggenberger E, Chalk C, Ringelstein M, Aktas O, Montalban X, Fechner K, Stöcker W, Ringelstein EB, Paul F, Wildemann B. Clinical, paraclinical and serological findings in Susac syndrome: an international multicentre study. Journal of Neuroinflammation 2014; 11: 46.

Jarius S, Paul F, Fechner K, Ruprecht K, Kleiter I, Franciotta D, Ringelstein M, Pache F, Aktas O, Wildemann B. Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. Journal of Neuroinflammation 2014; 11: 129.

Jost W, Hefter H, Reissig A, Kollewe K, Wissel J. Efficacy and safety of botulinum toxin A (Dysport) for the treatment of arm spasticity: Results of the German-Austrian open-label post-marketing surveillance prospective study. Journal of Neurological Sciences 2014; 337: 86-90.

Jütten K, Pieperhoff P, Südmeyer M, Schleicher A, Ferrea S, Caspers S, Zilles K, Schnitzler A, Amunts K, Lux S. Neuropsychological and brain volume differences in patients with left- and right-beginning corticobasal syndrome. PLoS One 2014; 9: e110326.

Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; for the ATAMS Study Group. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double blind, phase 2 trial. Lancet Neurology 2014; 13: 353-363.

Kieseier BC. The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interfon beta treatments. Expert Reviews inNeurotherapeutics 2014; 14: 105-120.

Kieseier BC, Wiendl H. (Editorial) New evidence for teriflunomide in multiple sclerosis. Lancet Neurology 2014; 13: 234-235.

Kieseier BC. Definig a role for laquinimod in multiple sclerosis. Therapeutic Advances in Neurological Disorders 2014; 7: 195-205.

Kieseier BC. Die Nervenbiopsie ist eine sinnvolle Maßnahme bei der Diagnostik von Polyneuropathien - Kontra. Aktuelle Neurologie 2014; 41: 417-419.

Klepp A, Weissler H, Niccolai V, Terhalle A, Geisler H, Schnitzler A, Biermann-Ruben K. Neuromagnetic hand and foot motor sources recruited during action verb processing. Brain and Language 2014; 128: 41-52.

Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; for the GALILEO Study Group. Ophthalmology 2014; 121: 202-208.

Kovacs Z, Schacht T, Herrmann AK, Albrecht P, Lefkimmiatis K, Methner A. Protein kinase inhibitor b enhances the constitutive activity of G-protein-coupled zinc receptor GPR39. The Biochemical Journal 2014; 462: 125-132.

Krause V, Wach C, Südmeyer M, Ferrea S, Schnitzler A, Pollok B. Cortico-muscular coupling and motor performance are modulated by 20 Hz transcranial alternating current stimulation (tACS) in Parkinson's disease. Frontiers in Human Neuroscience 2014; 7: 928.

Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Multiple Sclerosis2014; 20: 843-847.

Kroll T, Elmenhorst D, Weisshaupt A, Beer S, Bauer A. Reproducibility of non-invasive A1 adenosine receptor quantification in the rat brain using [(18)F]CPFPX and positron emission tomography. Molecular Imaging and Biology 2014; 16: 699-709.

Kroll T, Elmenhorst D, Matusch A, Celik AA, Wedekind F, Weisshaupt A, Beer S, Bauer A. [¹⁸F] Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT₂A receptor densities in the rat brain. Molecular Imaging and Biology 2014; 41: 1-9.

Lee JI, Jander S, Oberhuber A, Schelzig H, Hänggi D, Turowski B, Seitz RJ. Stroke in patients with occlusion of the internal carotid artery: options for treatment. Expert Review of Neurotherapeutics 2014; 14: 1153-1167.

Lehmann HC, Dalakas MC, Hartung HP. Immunology of demyelinating immune neuropathies. In: Aminoff MJ, Daroff RB (eds). Enceclopedia of the Neurological Sciences. Oxford: Academic Press, 2014, 2nd edition, vol. 2, 684-687.

Leist TP, Comi G, Cree B, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; on behalf of the oral cladribine for early MS (ORACLE MS) Study Group. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology 2014; 13: 257-267.

Lemmon VP, Ferguson AR, Popovich PG, Xu XM, Snow DM, Igarashi M, Beattie CE, Bixby JL; MIASCI Consortium, [Müller HW]. Minimum information about a spinal cord injury experiment: a proposed reporting standard for spinal cord injury experiments. Journal of Neurotrauma 2014; 31: 1354-1361.

Leuenberger T, Pfueller CF, Luessi F, Bendix I, Paterka M, Prozorovski T, Treue D, Luenstedt S, Herz J, Siffrin V, Infante-Duarte C, Zipp F, Waiczies S. Modulation of dendritic cell immunobiology via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. PLoS One 2014; 9: e100871.

Levin E, Leibinger M, Andreadaki A, Fischer D. Neuronal expression of muscle LIM protein in postnatal retinae of rodents. PLoS One 2014; 9: e100756.

Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber MS, Stüve O. Immunopathogenesis of neuromyelitis optica. Advances in Immunology 2014; 121: 213-242.

Lewerenz J, Baxter P, Kassubeck R, Albrecht P, Van Liefferiinge J, Westhoff MA, Halatsch ME, Meakin PJ, Karpel-Massler G, Hayes JD, Aroni E, Smolders I, Ludolph A, Methner A, Massie A, Hardingham GE. Maher P. Phosphpoinositide-3 kinases upregulate system xc - via elF2alphga and ATF4 - a pathway active in glioblastomas and epilepsy. Antioxidants & Redox Signalling 2014; 20: 2907-2922.

Li ZX, Lu CZ, Zhang XH, Cui LY, Xu XH, Radue E, Chu SG, Wang LR, Beckmann K, Lampe J, Pohl C, Stemper B, Sandbrink R. Interferon beta-1b is effective and has a favourable safety profile in Chinese patients with relapsing forms of multiple sclerosis. Neurologia 2014; 19: 179-189.

Lill CM, Schilling M, Ansaloni S, Schröder J, Jaedicke M, Luessi F, Schjeide BM, Mashychev A, Graetz C, Akkad DA, Gerdes LA, Kroner A, Blaschke P, Hoffjan S, Winkelmann A, Dörner T, Rieckmann P, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Zipp F, Bertram L. Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics 2014; 15: 129-134.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Definig the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-286.

Mathys C, Hoffstädter F, Caspers J, Caspers S, Südmeyer M, Grefkes C, Eickhoff SB, Langner R. An age-related shift of resting-state functional connectivity of the subthalamic nucleus: a potential mechanism for compensating motor performance decline in older adults. Frontiers in Aging Neuroscience 2014; 6: 178.

Matusch A, Saft C, Elmenhorst D, Kraus PH, Gold R, Hartung HP, Bauer A. Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging 2014; 41: 1210-1220.

May ES, Butz M, Kahlbrock N, Brenner M, Hoogenboom N, Kircheis G, Häussinger D, Schnitzler A. Hepatic encephalopathy is associated with slowed and delayed stimulus-associated somatosensory alpha activity. Clinical Neurophysiology 2014; 125: 2427-2435.

Menge T, Stüve O, Kieseier BC, Hartung HP. Alemtuzumab: The advantages and challenges of a novel therapy in MS. Neurology 2014; 83: 87-97.

Meyer zu Hörste G, Mausberg AK, Cordes S, El-Haddad H, Partke HJ, Leussink VI, Roden M, Martin S, Steinman L, Hartung HP, Kieseier BC. Thymic epithelium determines a spontaneous chronic neuritis in Icam 1tm1JcgrNOD mice. Journal of Immunology 2014; 193: 2678-2690.

Meyer zu Hörste G, Cordes S, Mausberg AK, Zozulya AL, Wessig C, Sparwasser T, Mathys C, Wiendl H, Hartung HP, Kieseier BC. FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies. PLoS One 2014; 9: e108756.

Müller AK, Blasberg C, Südmeyer M, Aktas O, Albrecht P. Photoreceptor layer thinning in parkinsonian syndromes. Movement Disorders 2014; 29: 1222-1223.

Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Annals of Clinical and Translational Neurology 2014; 1: 605-617.

Muthuraman M, Hellriegel H, Hoogenboom N, Anwar AR, Mideksa KG, Krause H, Schnitzler A, Deuschl G, Raethjen J. Beamformer source analysis and connectivity on concurrent EEG and MEG data during voluntary movements. PLoS One 2014; 9: e91441.

Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, Barkhof F. Interferon-beta 1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis 2014; 20: 234-242.

Niccolai V, Klepp A, Weissler H, Hoogenboom N, Schnitzler A, Biermann-Ruben K. Grasping hand verbs: oscillatory beta and alpha correlates of action-word processing. PLoS One 2014; 9: e108059.

Oberwahrenbrock T, Balk L, Petzold A, Brandt AU. Albrecht P. Re: Garcia-Martin et al.: Retinal layer segmentation in patients with multiple sclerosis using spectral domain optical coherence tomography (Ophthalmology 2014; 121: 573-9). Ophthalmology 2014; 121: e63.

Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Niemeyer F, Stemper B, Zeitz O, Sandbrink R; Galileo Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion; 18-month results of the phase 3 GALILEO Study. American Journal of Ophthalmology 2014; 158: 1032-1038.

Oreja-Guevara C, Wiendl H, Kieseier BC, Airas L; NeuroNet Study Group. Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. Therapeutic Advances in Neurological Disorders 2014; 7: 137-149.

Paassen B, Stöckel A, Dickfelder R, Göpfert JP, Kirchhoffer T, Brazda N, Müller HW, Klinger R, Hartung M, Cimiano P. Ontology-based extraction of structured information from plublications on preclinical experiments for spinal cord injury treatments. Proceedings of Third Workshop on Semantic Web and Information Extraction 2014; 25-32.

Pavlidou A, Schnitzler A, Lange J. Distinct spatio-temporal profiles of beta-oscillations within visual and sensorimotor areas during action recognition as revealed by MEG. Cortex 2014; 54: 106-116.

Pollok B, Latz D, Krause V, Butz M, Schnitzler A. Changes of motor-cortical oscillations associated with motor learning. Neuroscience 2014; 275: 47-53.

Prestel J, Volkers P, Mentzer D, Lehmann HC, Hartung HP, Keller-Stanislawski B; for the GBS Study Group. Risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination in Germany. Pharmacoepidemiology and Drug Safety 2014; 23: 1192-1204.

Prochnow D, Brunsheim S, Steinhäuser L, Seitz RJ. Reasoning about the implications of facial expressions: A behavioural and fMRI study on low and high social impact. Brain and Cognition 2014; 90: 165-173.

Ringelstein M, Aktas O, Harmel J, Prayer D, Jarius S, Wildemann B, Hartung HP, Salhofer-Polanyi S, Leutmezer F, Rommer PS. Biopsie bei tumorverdächtiger spinaler Raumforderung: Fallstrick Neuromyelitis optica. Nervenarzt 2014; 85: 1298-1303.

Ringelstein M, Kleiter I, Ayzenberg I, Borisow N, Paul F, Ruprecht K, Kraemer M, Cohn E, Wildemann B, Jarius S, Hartung HP, Aktas O, Albrecht P. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Multiple Sclerosis 2014; 20: 617-620.

Ringelstein M, Metz I, Ruprecht K, Koch A, Rappold J, Ingwersen J, Mathys C, Jarius S, Brück W, Hartung HP, Paul F, Aktas O, for the Neuromyelitis Optica Study Group (NEMOS). Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis 2014; 20: 882-888.

Ringelstein M, Albrecht P, Südmeyer M, Harmel J, Müller AK, Keser N, Finis D, Ferrea S, Guthoff R, Schnitzler A, Hartung HP, Methner A, Aktas O. Subtle retinal pathology in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology 2014; 4: 290-297.

Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, Lehmann HC. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) Journal of Neuroimmunology 2014; 274: 225-229.

Rommer PS, Zettl U, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O. Requirement for safety monitoring for approved MS therapies. - An overview. Clinical and Experimental Immunology 2014; 175: 397-407.

Sasada S, Kato K, Kadowaki S, Groiss SJ, Ugawa Y, Komiyama T, Nishimura Y. Volitional walking via upper limb muscle-controlled stimulation of the lumbar locomotor center in man. Journal of Neuroscience 2014; 34: 11131-11142.

Scherfeld D, Bien CG. Antikörper-vermittelte Epilepsien. Klinische Neurophysiologie 2014; 45: 222-229.

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Ngyuen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six week results of the VIEW Studies. Ophthalmology 2014; 121: 193-201.

Schnitzler A, Timmermann L. Tiefe Hirnstimulation - best clinical practise und neue experimentelle Felder. Klinische Neurophysiologie 2014; 45: 83-84.

Schu S, Slotty PJ, Bara G, von Knop M, Edgar D, Vesper J. A prospective, randomised, double-blind, placebo-controlled study to examine the effectiveness of burst spinal cord stimulation patterns for the treatment of failed back surgery syndrome. Neuromodulation2014; 17: 443-450.

Schüpbach WM, Rau J, Houeto JL, Krack P, Schnitzler A, Schade-Brittinger C, Timmermann L, Deuschl G. Myths and facts about the EARLYSTIM study. Movement Disorders 2014; 29: 1742-1750.

Schumacher L, Urbach A, Lutzenburg M, Bidmon HJ, Witte OW. Bihemispheric ischemic tolerance induced by a unilateral focal cortical lesion. Brain Research 2014; 1570: 54-60.

Skodda S, Grönheit W, Schlegel U, Südmeyer M, Schnitzler A, Wojtecki L. Effect of subthalamic stimulation on voice and speech in Parkinson's disease: for the better or worse? Frontiers in Neurology 2014; 4: 218.

Stangel M, Penner IK, Kieseier BC. Defining the new end point for multiple sclerosis treatment. JAMA Neurology 2014; 71: 1056-1057.

Stettner M, Lohmann B, Wolffram K, Weinberger JP, Dehmel T, Hartung HP, Mausberg AK, Kieseier BC. Interleukin-17 impedes Schwann cell-mediated myelination. Journal of Neuroinflammation 2014; 11: 63.

Stettner M. The Lindau Nobel Laureate Meeting 2014 - do something that you enjoy! Journal of the Peripheral Nervous System 2014; 19: 343.

Striepens N, Matusch A, Kendrick KM, Mihov Y, Elmenhorst D, Becker B, Lang M, Coenen HH, Maier W, Hurlemann R, Bauer A. Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. Psychoneuroendocrinology 2014; 39: 74-87.

Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V. CD19 as a molecular target in CNS autoimmunity. Acta Neuropathologica 2014; 128: 177-190.

Stüve O, Marder E, Okai A, Stettner M, Kieseier BC. Heat exposure and bicycling trigger recurrent aseptic meningitis: a case report. BMC Neurology 2014; 14: 1061.

Stutzki H, Leibig C, Andreadakai A, Fischer D, Zeck G. Inflammatory stimulation preserves physiological properties of retinal ganglion cells after optic nerve injury. Frontiers in Cellular Neurosciences 2014; 8: 38.

Thomalla G, Jonas M, Bäumer T, Siebner HR, Biermann-Rben K, Ganos C, Orth M, Hummel FC, Gerloff C, Müller-Vahl K, Schnitzler A, Münchau A. Costs of control: decreased motor cortex engagement during a Go/NoGo task in Tourette's syndrome. Brain 2014; 137: 122-136.

Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T; Neuromyelitis Optica Study Group [Hartung HP]. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology 2014; 261: 1-16.

Tzekova N, Heinen A, Küry P. Molecules involved in the crosstalk between immune and peripheral nerve Schwann cells. Journal of Clinical Immunology 2014; 34: Suppl. 1: 86-104.

Volkmann J, Müller J, Deuschl G, Kühn AA, Krauss JK, Poewe W, Timmermann L, Falk D, [Schnitzler A]; DBS study group for dystonia. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurology 2014; 13: 875-884.

Wang J, Hirschmann J, Elben S, Hartmann CJ, Vesper J, Wojtecki L, Schnitzler A. High-frequency oscillations in Parkinson's disease: spatial distribution and clinical relevance. Movement Disorders 2014; 29: 1265-1272.

Warnke C, Adams O, Kieseier B. Relevance of CD34+ cells as a reservoir for JC virus in patient swith multiple sclerosis. JAMA Neurology 2014; 71: 1192.

Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology 2014; 83: 2153-2157.

Warnke C, Kieseier BC. Teriflunomid - Neue orale Option zur Behandlung der schubförmigen multiplen Sklerose. Arzneimitteltherapie 2014; 32: 41-45.

Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology 2014; 76: 792-801.

Weber A, Zimmermann C, Kieseier BC, Hartung HP, Hofstetter HH. Bacteria and their cell wall components uniformly co-activate IL-17-producing thymocytes. Clinical and Experimental Immunology 2014; 178: 504-515.

Wojtecki L, Elben S, Südmeyer M, Vesper J, Schnitzler A. The rhythm of the executive gate of speech: subthalamic low-frequency oscillations increase during verbal generation. European Journal of Neuroscience 2014, in press.

Wojtecki L, Petri D, Elben S, Hirschmann J, Yelnik J, Eickhoff S, Vesper J, Schnitzler A. Modulation of central thalamic oscillations during emotional-cognitive processing in chronic disorder of consciousness. Cortex 2014; 60: 94-102.

Wojtecki L. Tiefe Hirnstimulation bei Zwangsstörungen. Klinische Neurophysiologie 2014; 45: 118-121.

Zenker J, Stettner M, Ruskamo S, Domènech-Estévez E, Baloui H, Médard JJ, Verheijen MH, Brouwers JF, Kursula P, Kieseier BC, Chrast R. A role of peripheral myelin protein 2 in lipid homeostasis of myelinating schwann cells. Glia 2014; 62: 1502-1512.

MediathekInformation und Wissen
LageplanSo finden Sie uns